RareCyte Secures $500K Gates Foundation Grant to Study Circulating Trophoblasts in Fetal Growth Restriction

RareCyte, a precision biology and liquid biopsy innovator, received a $500K Gates Foundation award to advance research on fetal growth restriction (FGR), a major cause of preterm birth and neonatal complications. Using its TrophoSeq™ assay, RareCyte will non-invasively study placental cells from maternal blood, partnering with the University of Cape Town to profile pregnancies affected by early-onset FGR and matched healthy controls.